Apr 2, 2026 3-5pm ET
Thursday on The Robert Scott Bell Show:
Hour 1
Special Guest: Jonathan Emord
For the past 37 years, Jonathan W. Emord has litigated against the federal bureaucracy, winning over and over again. Ron Paul calls Jonathan “an expert in constitutional theory and history” and “an expert litigator with a long string of legal victories over the federal bureaucracy.” George Noory calls him “a Knight in Shining Armor” and “a warrior out to save our rights.” Congressmen Dan Burton and John Doolittle describe him as “an intellectual warrior for the rights and freedoms of people in America.” Jonathan has a unique, detailed knowledge of the federal bureaucracy, the deep state. He knows how to defeat it. Jonathan graduated from the University of Illinois (BA, political science and history, 1982) and DePaul University College of Law (JD, 1985). He served as an attorney in the Federal Communications Commission during the Reagan administration. A leading constitutional law and litigation expert, he is the author of five critically acclaimed books. He has won more cases against the Food and Drug Administration in federal court than any other attorney in American history, earning him the nickname “FDA Dragon Slayer.” He is a columnist for Townhall.com, PJ Media.com, Americangreatness.com, and the U.S.A. Today Magazine. He frequently appears on national radio and television programs. He is married to Sheryl Emord, and they have two children, twins Justice and Angelica. They reside in Clifton, Virginia.
Supreme Court Signals Strong Support for Medical Free Speech in Ruling Against Ban on Conversion Therapy In a significant 6-3 decision on March 24, 2026, the U.S. Supreme Court struck down California’s ban on so-called “conversion therapy” for minors, ruling that the law unconstitutionally restricted licensed therapists’ free speech rights by prohibiting them from discussing or offering certain counseling approaches aimed at helping individuals align their gender identity with their biological sex or explore underlying psychological factors contributing to gender dysphoria. The majority opinion, authored by Justice Clarence Thomas, held that the state’s prohibition on “sexual orientation change efforts” or “gender identity change efforts” constituted viewpoint discrimination under the First Amendment, as it singled out and suppressed one category of therapeutic speech while allowing opposing viewpoints that affirm and facilitate gender transition. The Court emphasized that professional speech by licensed therapists is fully protected, rejecting California’s argument that the ban was a permissible regulation of conduct rather than speech, and found that the law failed strict scrutiny because less restrictive alternatives — such as informed consent, parental involvement, and evidence-based disclosure of risks — could address concerns about potential harm without banning entire categories of counseling. The ruling signals strong judicial support for medical free speech and parental rights in sensitive areas involving gender dysphoria treatment, potentially affecting similar bans in other states and influencing ongoing litigation over restrictions on puberty blockers, cross-sex hormones, and surgical interventions for minors. Justice Samuel Alito’s concurrence stressed that the decision protects the ability of therapists to provide exploratory therapy addressing trauma, autism, social contagion, or family dynamics that may contribute to rapid-onset gender dysphoria, rather than immediately affirming and medicalizing the condition. Dissenting justices argued the ban was a valid regulation of professional conduct to protect vulnerable minors from therapies lacking strong evidence of benefit and potentially causing harm. The decision has been welcomed by parental rights and free speech advocates as a victory against compelled speech and viewpoint discrimination in healthcare, while LGBTQ+ advocacy groups expressed concern that it could enable therapies they view as harmful or discredited. The article frames the ruling as a broader affirmation of the principle that the government cannot silence licensed professionals from offering evidence-based or exploratory counseling options, even on contentious issues, and that parents retain primary authority over medical and psychological decisions for their minor children absent clear abuse or neglect. The case may have ripple effects on related debates over informed consent, medical freedom, and the limits of state power to dictate acceptable therapeutic approaches in mental health care.
White House Pushes Senate to Move Quickly on Casey Means Nomination The White House is pressing Senate Republicans to expedite confirmation of Dr. Casey Means, President Donald Trump’s nominee for a senior leadership role at the Department of Health and Human Services, urging a swift vote in the Senate Health, Education, Labor and Pensions (HELP) Committee and on the full floor to capitalize on her strong performance during the confirmation hearing and to advance the Make America Healthy Again (MAHA) agenda before the 2026 midterms. Means, a Stanford-trained former surgeon who left conventional medicine to focus on metabolic health and co-found Levels Health, impressed many senators with her calm, data-driven testimony emphasizing nutrition, lifestyle, and root-cause approaches to chronic disease rather than perpetual pharmaceutical management. White House officials view her confirmation as a key step toward implementing reforms that prioritize prevention, reduce ultra-processed food influence, scrutinize environmental toxins, and shift federal health priorities away from over-reliance on drugs and toward individualized, evidence-based care. Senate Majority Leader John Thune has indicated the committee will move quickly, with a markup session scheduled for next week, though some moderate Republicans have expressed reservations about her departure from traditional allopathic training and her advocacy for continuous glucose monitoring and dietary interventions over standard protocols. Democrats on the committee have signaled strong opposition, criticizing Means for lacking extensive government or large-scale administrative experience and for her alignment with Kennedy’s skepticism toward certain broad vaccine recommendations and pharmaceutical-centric models. The White House has been actively lobbying undecided senators, highlighting Means’ clinical background, entrepreneurial success in metabolic health technology, and ability to bridge integrative and conventional approaches, while emphasizing that her confirmation would bring fresh perspectives needed to address the chronic disease epidemic costing trillions annually. Pro-MAHA groups and medical students have launched grassroots campaigns contacting senators, sharing stories of metabolic health improvements through dietary change, and arguing that Means represents a patient-centered shift long overdue in federal health policy. The article notes that while Kennedy retains strong personal standing with Trump, the White House has exerted more oversight on HHS operations in recent weeks to ensure alignment with broader administration priorities, particularly on issues with potential midterm implications. Means’ nomination is seen as a test of the Senate’s willingness to support the MAHA vision of prevention-first healthcare, with her confirmation potentially unlocking further reforms in nutrition education for medical schools, scrutiny of food additives, and reevaluation of chronic disease management strategies.
The Drug Definition Trap: Why U.S. Law Blocks Truthful Information That Could Help You Recover Your Health U.S. law, through the Food, Drug, and Cosmetic Act and FDA regulations, effectively blocks the communication of truthful, science-based information about the health benefits of natural substances — including vitamins, minerals, herbs, and other dietary ingredients — by classifying any claim that a product can “diagnose, cure, mitigate, treat, or prevent” disease as making it a drug, subjecting it to expensive and lengthy drug approval processes that most natural product companies cannot afford, thereby creating a regulatory trap that prevents consumers from learning about legitimate, evidence-supported ways to support their health and recover from chronic conditions. The Alliance for Natural Health USA explains that under current FDA policy, even peer-reviewed studies demonstrating that a nutrient like vitamin D can reduce risk of certain diseases, or that turmeric/curcumin has anti-inflammatory effects, cannot be communicated on product labels or in marketing materials without the product being reclassified as an unapproved drug, leading to warning letters, seizures, or injunctions against companies that dare to share the science. This creates a perverse system where synthetic pharmaceuticals — often with serious side effects and marginal benefits — can make disease-treatment claims after expensive trials, while natural substances with centuries of traditional use and modern clinical evidence are silenced, forcing consumers to navigate health decisions without access to full information. The article details how the 1994 Dietary Supplement Health and Education Act (DSHEA) attempted to protect access by classifying supplements as foods and allowing structure/function claims, but subsequent FDA interpretations and court rulings have narrowed this protection by broadly defining “disease claims,” leaving companies hesitant to share even basic, substantiated information. ANH-USA argues this framework benefits the pharmaceutical industry by maintaining a monopoly on disease treatment language while suppressing competition from safer, often more affordable natural alternatives that address root causes rather than symptoms. The piece calls for legislative reform to clarify that truthful, evidence-based information about nutrients and herbs should not automatically trigger drug status, to create a safe harbor for peer-reviewed science on labels and marketing, and to restore the original intent of DSHEA by distinguishing between disease treatment claims and legitimate health support statements. It warns that without such changes, Americans will continue to be denied access to potentially life-changing information about natural health options, perpetuating a system that favors expensive, patentable drugs over prevention and self-care, ultimately harming public health and individual autonomy in an era of rising chronic disease. The article urges readers to contact lawmakers in support of bills that would protect free speech in health information and ensure consumers can make informed choices based on the best available science rather than regulatory barriers designed to protect industry interests.
Trump May Pull Out of ‘Paper Tiger’ NATO After Starmer Stiffs Strait Support President Donald Trump is reportedly considering a dramatic reduction or complete withdrawal of U.S. support for NATO following what he described as British Prime Minister Keir Starmer’s refusal to commit meaningful naval or military resources to defend the Strait of Hormuz against Iranian threats, with Trump calling the alliance a “paper tiger” that freeloads on American military power while European leaders offer only symbolic gestures during real crises. According to sources familiar with White House discussions, Trump was angered by Starmer’s response during a recent call where the UK prime minister expressed concern about oil price spikes but declined to deploy additional Royal Navy assets or join a U.S.-led coalition to secure the critical shipping lane through which roughly 20% of global oil passes, citing domestic budget constraints and political risks. Trump reportedly told aides that NATO members have repeatedly failed to meet the 2% GDP defense spending target and provide little reciprocal value when U.S. interests are directly threatened, with European contributions often limited to rhetorical support or small token forces. The article notes that Trump has long criticized NATO as obsolete and unfairly burdensome on the U.S., which shoulders the majority of the alliance’s military capabilities and funding, and that recent events in the Middle East have reinforced his view that the organization functions more as a one-way security guarantee for Europe than a true mutual defense pact. European leaders, including Starmer, have expressed alarm at the possibility of reduced U.S. commitment, warning that it could embolden adversaries like Russia, China, and Iran, but Trump’s inner circle views European reluctance to share burdens in the Strait of Hormuz as the final straw. The piece suggests that a U.S. pullback could involve slashing financial contributions, withdrawing troops from European bases, or conditioning Article 5 mutual defense obligations on reciprocal actions, potentially forcing NATO members to increase their own defense spending dramatically or face a fragmented alliance. Critics of Trump’s approach argue that NATO remains vital for collective security and deterring Russian aggression in Eastern Europe, while supporters contend that decades of U.S. subsidization have created dependency and that forcing Europe to take greater responsibility would strengthen rather than weaken the alliance in the long term. The article frames the situation as a pivotal moment in transatlantic relations, with Trump’s “America First” doctrine clashing against European expectations of continued U.S. protection without equivalent contributions, potentially reshaping global security arrangements if the U.S. significantly reduces its role in NATO.
Supreme Court to Hear Challenge to Trump’s Birthright Citizenship Order The U.S. Supreme Court agreed on March 27, 2026, to hear a challenge to President Donald Trump’s executive order ending birthright citizenship for children born in the United States to non-citizen parents who are in the country illegally or on temporary visas, granting certiorari in a consolidated case brought by several states and immigrant rights organizations that argues the order violates the 14th Amendment’s Citizenship Clause while the administration maintains that the clause was never intended to confer automatic citizenship on children of illegal aliens or temporary visitors. Trump issued the order in January 2025, directing federal agencies to interpret the 14th Amendment as applying only to children of U.S. citizens or legal permanent residents, citing historical intent, the clause’s original focus on freed slaves after the Civil War, and the need to end what he called “birth tourism” and “anchor baby” incentives that encourage illegal immigration. Lower courts issued conflicting rulings, with some blocking the order nationwide as unconstitutional while others upheld it as a valid exercise of executive authority to interpret ambiguous constitutional language in the absence of definitive Supreme Court precedent directly addressing children of illegal immigrants. The Supreme Court will now resolve the circuit split, with arguments expected in the fall 2026 term and a decision likely by June 2027. The administration argues that the 14th Amendment’s phrase “subject to the jurisdiction thereof” excludes those present illegally or on temporary status who owe primary allegiance to foreign governments, citing Senate debates during ratification and Supreme Court dicta in cases like Elk v. Wilkins (1884) that limited birthright citizenship for certain non-citizens. Challengers contend that the clause has been consistently interpreted for over a century to grant citizenship to anyone born on U.S. soil regardless of parental status, with the sole exception of children of foreign diplomats, and that any change requires a constitutional amendment rather than executive action. The case has drawn intense interest from immigration policy experts, with supporters of the order arguing it would reduce incentives for illegal immigration and ease pressure on public services, while opponents warn it could create a stateless underclass, disrupt families, and invite constitutional crisis by allowing the president to unilaterally reinterpret foundational amendments. Legal scholars expect the Court’s conservative majority to closely examine original public meaning and historical context, potentially narrowing or redefining the scope of birthright citizenship for the first time in modern history. The article notes that a ruling in favor of Trump could have sweeping implications for immigration enforcement, census counting, and future executive actions on constitutional interpretation, while a decision against the order would reinforce long-standing precedent and limit presidential power to alter citizenship rules without congressional or amendment processes.Hour 2
Exclusive: Pfizer, BioNTech Halt U.S. COVID Vaccine Study After Recruitment Struggles Pfizer and BioNTech have quietly halted enrollment in a large U.S.-based clinical trial for an updated COVID-19 vaccine formulation targeting newer variants, citing significant difficulties recruiting participants amid declining public interest in additional boosters and growing skepticism toward mRNA technology following safety concerns and shifting federal recommendations under the current administration. The Phase 3 study, which aimed to enroll tens of thousands of participants to evaluate efficacy and safety of a monovalent or bivalent candidate against recent Omicron subvariants, was paused indefinitely after months of low enrollment rates, with internal documents showing that many potential volunteers expressed reluctance due to reports of myocarditis, pericarditis, and other adverse events, as well as the perception that COVID-19 now poses minimal risk to healthy individuals and that natural immunity or prior infection provides sufficient protection. Sources familiar with the decision told U.S. News that Pfizer-BioNTech executives determined that continuing the trial under current conditions would be unlikely to yield statistically robust data within a reasonable timeframe, particularly as federal guidance has moved away from universal boosting toward shared clinical decision-making for lower-risk groups. The companies have not issued a public statement on the pause, but the move aligns with broader industry trends of scaled-back COVID-19 vaccine development as demand plummets and governments reduce procurement contracts. The halt comes as the CDC and ACIP continue to reevaluate recommendations, with recent meetings focusing on whether updated formulations still meet criteria for routine use given lower disease severity and the availability of natural immunity data. Public health experts expressed concern that recruitment struggles reflect eroded trust in mRNA platforms and vaccine policy more broadly, potentially complicating future pandemic preparedness efforts if novel variants emerge. The article notes that while Pfizer and BioNTech continue to market existing formulations internationally and for high-risk populations, the U.S. trial pause underscores the challenges of sustaining interest in COVID-19 boosters in a post-emergency environment where the virus is increasingly viewed as endemic rather than an existential threat. The development may influence ongoing debates over liability protections, long-term safety monitoring, and the appropriate role of novel vaccine technologies in routine immunization schedules.
Special Guest: Ryan Richardson
A calm, modern translator of what is happening in the American food system — and what it means for families. It’s Ryan Richardson — Nutrition-First Health Advocate & Second-Generation Natural Health Educator. Ryan focuses on prevention, forgotten nutrients, and long-term family wellness. Ryan Richardson is a nutrition-first health educator and President of Richardson Nutritional Center who helps families understand how the food system is quietly changing — and what those changes mean for everyday health decisions. Through his twice-weekly Substack and growing social media presence, Ryan translates shifts in grocery standards, ingredient reformulation, dietary guidance, and food access into practical, grounded conversations that reduce confusion and build confidence.
Ryan was raised in a family shaped by prevention-first values and the legacy of his grandfather, Dr. John A. Richardson, MD, Ryan brings a rare long-view perspective on nutrition, wellness, and health trends. With studies in biochemistry and hands-on experience across sourcing, manufacturing, and quality standards, he bridges ancestral nutritional wisdom with modern responsibility and transparency—offering thoughtful conversations on family health, prevention, and long-term wellness.
Welcome back to another “Homeopathic Hits” episode on The Robert Scott Bell Show!
Today’s Homeopathic Hit is Calcarea arsenicosa, Arsenite of Lime.
Boericke presents this remedy as especially suited to fleshy women around the climacteric, with symptoms of palpitation, dyspnoea, weakness, and dropsy, along with albuminuria and renal sensitivity. Its sphere includes chronic systemic conditions such as malaria, enlarged liver and spleen in children, and low hemoglobin states.
Download the Information Sheet
Remember Friends, The Power to Heal is Yours!
